DRUG DISCOVERY BIOLOGY

STRATEGY MEETING EAST COAST USA 2024

Tuesday, 12th November 2024 **Le Meridien Cambridge**

Assessing, Choosing And Optimizing The Right Set Of Data And Methodologies To Help With Finding Effective Modalities And Techniques For Drug Discovery Biology

Featuring Industry Leaders and Decision Makers:

Cara Williams
Vice President
Head of Preclinical Biology, Inflammation & Immunology Research Unit
Pfizer

Prasoon Chaturvedi
Vice President, Head of DMPK
C4 Therapeutics

Diane Joseph-McCarthy
Executive Director, Bioengineering Technology & Entrepreneurship Center
Boston University

Martin Marro
Executive Director, Cell Pharmacology, Obesity & Complications
Eli Lilly and Company

Huseyin Mehmet
Executive Director. New Ventures
University of Massachusetts Medical School

Hongwei Han
Associate Director, Head of In Vivo Pharmacology
Generate: Biomedicines

Mohammad Shadid
Vice President, Preclinical Development
Korro Bio

Bertrand Le Bourdonnec
Chief Scientific Officer
HDAX Therapeutics

19 ROUNDTABLE DISCUSSIONS

6 TRACKS

2 KEYNOTE PRESENTATIONS

1 PANEL DISCUSSION

1 LOCATION

What Makes Our Strategy Meetings So Unique?

Proud to Partner with:

Sai · PELAGO BIOSCIENCE · revvity signals · evotec · sapio sciences · aragen · NovAliX

PROVENTA INTERNATIONAL

proventainternational.com

UK: +44 (0)208 124 6417
US: +1 (617) 340 2564

info@proventainternational.com
Proventa International

@proventaintl
@proventainternational

Proventa International's Strategy Meetings are a completely unique experience.

DRUG DISCOVERY BIOLOGY
STRATEGY MEETING EAST COAST USA 2024
Tuesday, 12th November 2024 Le Meridien Cambridge

We're committed to delivering long-term value across our extensive life science network. Through our carefully crafted meetings, collaborative experiences and services Proventa International can offer you the perfect opportunity to meet your business goals, whatever they may be.

Our Vision

To be a platform for creating life-saving therapies and to facilitate the creation of a completely patient centric pharmaceutical industry.

Our Mission

By encouraging key leaders and their companies to put the patient at the very heart beat of every innovation. Sharing valuable insights and strategies to assist in the discovery, development and commercialisation of life saving therapies.

Our Unique Meeting Format

ROUNDTABLE DISCUSSIONS
These interactive and informal discussion groups are the hallmark of the meeting. The brightest minds in the industry are brought together in 60-minute sessions that enable participants from all over the world to share ideas, challenges and lessons learned.

PERSONALISED AGENDA
Each delegate receives a personalised agenda with the roundtable discussions that you choose. You only attend sessions and meetings that fit your challenges and interests, ensuring your time spent is focused and well-utilised.

INNOVATIVE SOLUTIONS
The most effective and time efficient way to assess potential partners at a strategic level. Identify key solution providers that can take your business to the next level and we will help arrange private meetings so you can connect.

STRATEGIC NETWORKING
Strategic networking opportunities form a key benefit of the meeting. Our proven format for building and strengthening alliances to make lasting connections that benefit you.

Seniority of Attendees

- Director Level
- President / VP
- Department Head
- Other
- Team Lead
- C-Level
- Scientist
- Academia
- Manager
- Biology Specialist



Biology

- Biology
- R&D
- Drug Discovery
- Bioinformatics
- DMPK
- ADME
- Toxicology
- Structural Biology
- Pre-Clinical

Meet Investors

- Venture Capital
- Private Equity
- Large Pharma/Biotech
- Corporate Venture Capital
- Institutional
- High Net Worth
- Family Office/Private Wealth
- Government Organisation/
- Sovereign Wealth Fund
- Angel

proventainternational.com
UK: +44 (0)20 3314 0100
US: +1 (617) 614 0377
info@proventainternational.com
Proventa International
@proventaintl
@proventainternational
PROVENTA INTERNATIONAL

Facilitator Faculty

Carlos Pedraza
AVP Biology
Sai Life Sciences

Jonathan Castillo
Associate Director Biology & Biophysics
Sai Life Sciences

Zev Wisotsky
Director of Drug Discovery Informatics
Revvity Signals

Andrea Weston
Executive Director, Cellular, Genomic, and Protein Sciences
Pfizer

Anitha Krishnan
Executive Director, Research
Aviceda Therapeutics

Bertrand Le Bourdonnec
Chief Scientific Officer
HDAX Therapeutics

Cara Williams
Vice President Head of Preclinical Biology, Inflammation & Immunology Research Unit
Pfizer

Changyun Hu
Chief Scientific Officer
Adept Therapeutics

David Winkler
Executive Director Biology
IFM Therapeutics

Diane Joseph-McCarthy
Executive Director, Bioengineering Technology & Entrepreneurship Center
Boston University

Deepika Sharma Das
Director, Portfolio Strategy & Partnerships, Global Research & Early Development
Novo Nordisk

Dhruv Sethi
Senior Director, Discovery
Obsidian Therapeutics



Hongwei Han
Associate Director, Head of In Vivo Pharmacology
Generate:Biomedicines

Huseyin Mehmet
Executive Director. New Ventures
University of Massachusetts Medical School

Jason Wu
Machine Learning Scientist II
Sanofi

Kevin Knockenhauer
Associate Director
Accent Therapeutics

Kyriakos Economides
Vice President
Ampersand Biomedicines

Larry R. Brown
Executive Vice President, Chief Scientific Officer
Noveome Biotherapeutics, Inc.

Laura Zawadzke
Executive Director of Chemical and Structural Biology
LifeMine Therapeutics

Martin Marro
Executive Director, Cell Pharmacology, Obesity & Complications
Eli Lilly and Company

Mohammad Shadid
Vice President, Preclinical Development
Korro Bio

Prasoon Chaturvedi
Vice President, Head of DMPK
C4 Therapeutics

2024 Sponsors

THOUGHT LEADER

Sai Life Sciences is a full-service CDMO driven by a vision to support the launch of 25 new medicines with our partners by 2025. Sai Life Sciences provides services to our pharma innovator partners, which accelerate the discovery, development and manufacture of complex small molecule therapeutic agents. Our clients gain clear competitive advantages through shorter time to market and risk minimization using our integrated and high-quality scientific services. Established in 1999, Sai has over 2,000 employees located at six R&D and manufacturing sites in India, the UK and USA. As one of India's fastest growing CDMOs, the company is investing over US $ 150 M in augmenting its R&D and manufacturing capabilities, including setting up a Biology Lab in Cambridge, Mass. (USA) and a Process R&D Lab in Manchester, UK. Sai provides high value integrated services in all areas of chemistry from hit discovery to GMP manufacturing, pharmacology, DMPK, toxicology and formulation development to better support the increasing needs of our customers. Sai Life Sciences is backed by TPG Capital and HBM Healthcare Investments.

PARTNERING SPONSORS

Pelago Bioscience is a Discovery Research Partner focusing on biologically relevant systems, unleashing drug discovery projects using the patented CETSA® technology as a core pillar. The Cellular Thermal Shift Assay (CETSA® by Pelago Bioscience) has multiple assay formats that make it a keystone of decision making throughout the drug discovery pipeline. Unlike other solutions on the market today, its unique approach allows the assessment and quantification of target engagement under physiological conditions – without the need to modify the compound or protein. This provides data that is both actionable and biologically relevant. Think of CETSA® as snapshots of true target engagement inside the cell, any time you need them. Using CETSA® data and applications, our customers are able to make better and more informed decisions at earlier stages in their projects.

Revvity Signals Software formerly known as PerkinElmer Informatics offers one of the most comprehensive suites of scientific software in the world. Our future-proof technology enables investigators in Life Sciences to capture and analyze their data from initial research and development of their therapeutics, through biomarker discovery & patient stratifications and ultimately live tracking of their clinical trials. From our internationally recognized flagship ChemDraw® to our Signals Research Suite (Signals Notebook, Signals VitroVivo, and Signals Inventa)to our exclusive TIBCO® Spotfire® partnership that brings scientific data analytics to visual life in both

With a firm grasp on design, synthesis, analysis, and characterization, coupled with profound understanding of the biological and non-efficacy aspects of drug action, Drug Discovery Chemistry serves as the foundation for innovation and intellectual property protection, ultimately yielding significant value for our partners. At **Evotec**, we recognize the unique needs, capabilities, capacities, and philosophies of each partner, and thus we strive to offer flexible, innovative, and efficient chemistry solutions tailored to their specific requirements and goals. Our Drug Discovery Chemistry team boasts a remarkable track record of success across diverse compound types, target classes, routes of administration, and disease areas. We are equipped to support our partners' programs at every phase of the chemical value stream, including hit creation, expansion, hit-to-lead, lead optimization, and development readiness. The scientific excellence and efficacy of all our chemistry endeavors are overseen by a leadership team with unparalleled levels of expertise, breadth of knowledge, and successful outcomes. Our comprehensive range of capabilities can be blended to provide needed or combined project solutions. These capabilities include: Cutting-edge molecular design, Efficient and rapid synthetic execution, Route development and scale-up chemistry, Preparative chromatography services, Drug metabolism and pharmacokinetics (DMPK), Solid state characterization and formulation support, Expert guidance on overall project strategy, Development and implementation of IP protection strategies, Effective project management At Evotec, our chemistry groups are strategically co-located with DMPK and computational chemistry teams. This close proximity enables seamless communication and collaboration, allowing us to swiftly leverage combined experience and intellect when addressing interdisciplinary drug discovery challenges. This integrated approach facilitates rapid "design-make-test-analyze" cycles, particularly when clients require access to multiple activities to support their programs.

Sapio Sciences mission is to improve life in the lab - because science is complex, Sapio makes technology simple. Sapio is a global business offering an all-in-one science-aware (TM) lab informatics platform combining cloud-based LIMS, ELN, and data solutions. Sapio serves some of the largest global and niche brands, including biopharma, CRO's and clinical diagnostic labs across NGS genomic sequencing, bioanalysis, bioprocessing, stability, clinical, histopathology, drug research, and in vivo studies. Our customers love Sapio's platform because it is robust, scalable, and with no-code configuration, can quickly adapt to meet unique needs."

Aragen Life Sciences (formerly, GVK BIO), is a leading R&D and manufacturing solutions provider for the life sciences industries worldwide. It offers end-to-end integrated or standalone solutions for small and large molecules. Established in 2001, the Company operates through a network of sites located globally with a team of 3000+ scientists and 450+ PhDs. Its expertise and experience have enabled over 450 customers in advancing their research programs from discovery through commercialization. Aragen's innovative mindset, infrastructure, flexible business models have enabled us to serve large pharma, biotech, agrochemical, animal health, and performance chemical industries globally. Visit www.aragen.com for more details.

KEY OPINION LEADER

NovAliX

Agenda at a Glance

DRUG DISCOVERY BIOLOGY
STRATEGY MEETING EAST COAST USA 2024
Tuesday, 12th November 2024 | Le Meridien Cambridge

TIME EST	TRACK 1 TARGET IDENTIFICATION & HIT VALIDATION	TRACK 2 DMPK / ADME & TOXICOLOGY	TRACK 3 IN VIVO AND IN VITRO PHARMACOLOGY	TRACK 4 STRUCTURAL BIOLOGY AND BIOPHYSICS	TRACK 5 IN SILICO BIOLOGY	TRACK 6 STRATEGIC PARTNERSHIPS, INVESTMENT & COLLABORATIONS
BOARDROOM ►	Jerome C. Hunsaker A	Jerome C. Hunsaker B	Jerome C. Hunsaker C	Edward Pennell Brooks	Margaret L.A. Macvicar	Lan Jen Chu
08:00 - 08:30	BREAKFAST & REGISTRATION					
08:30 - 09:00	**OPENING KEYNOTE PRESENTATION: An Emerging Paradigm: Cellular Therapeutics without Cells** PRESENTER: Larry R. Brown, *Executive Vice President, Chief Scientific Officer*, Noveome Biotherapeutics, Inc.					
09:00 - 10:00 PHARMA/ BIOTECH	**Moving from target identification to novel small molecule leads: Strategies for target validation, defining a target modulation profile, and setting up a successful hit-ID campaign** Andrea Weston, *Executive Director, Cellular, Genomic, and Protein Sciences*, Pfizer	**Assessing current advancements in PBPK absorption modeling and its challenges** Prasoon Chaturvedi, *Vice President, Head of DMPK*, C4 Therapeutics	**Enhancing Preclinical dose projection with appropriate biomarkers to facilitate clinical development** Cara Williams, *Vice President Head of Preclinical Biology, Inflammation & Immunology Research Unit*, Pfizer	**Unveiling Drug Targets: The Crucial Role of Structural Biology and Biophysics in Modern Drug Discovery** Kevin Knockenhauer, *Associate Director*, Accent Therapeutics	**Evaluating practical uses of latest AI/ML tools to expedite and increase efficiency in drug discovery process** Diane Joseph-McCarthy, *Executive Director, Bioengineering Technology & Entrepreneurship Center*, Boston University	
10:00 - 10:05	REFRESHMENT BREAK					
10:05 - 10:25	NETWORKING / 1-1 MEETINGS					
10:25 - 10:45	NETWORKING / 1-1 MEETINGS					
10:45 - 11:05	NETWORKING / 1-1 MEETINGS					
11:10 - 12:10 SOLUTION	**Recent Headways into PROTACs, Molecular Glues, PPIs as Pharmacological Targets** Carlos Pedraza, *AVP Biology*, Sai Life Sciences SAI LIFE SCIENCES Sai		**Opportunities and risks in the preclinical development of molecules that do not cross react with rodents** Anitha Krishnan, *Executive Director, Research*, Aviceda Therapeutics	**Conceptualizing Drug-Target Interactions at the Next Level: Targeted Protein Degraders** Jonathan Castillo, *Associate Director Biology & Biophysics*, Sai Life Sciences SAI LIFE SCIENCES Sai		
12:15 - 13:15 PHARMA/ BIOTECH	**Enumerating Criteria Selection Of Appropriate Modalities And Hit ID Strategies For First In Class Targets** Martin Marro, *Executive Director, Cell Pharmacology, Obesity & Complications*, Eli Lilly and Company	**Utility of Microphysiological Systems in the Drug Development of Oligonucleotide Therapeutics** Mohammad Shadid, *Vice President, Preclinical Development*, Korro Bio		**Applications of Structural Biology and Biophysics in Cell and Gene Therapies** Dhruv Sethi, *Senior Director, Discovery*, Obsidian Therapeutics	**Harnessing the promise of generative AI to transform drug discovery hence forward** Jason Wu, *Machine Learning Scientist II*, Sanofi	**Leveraging on academic partnerships to further drug discovery and development operations** Huseyin Mehmet, *Executive Director, New Ventures*, University of Massachusetts Medical School
13:15 - 14:00	NETWORKING LUNCH					
14:00 - 14:20	NETWORKING / 1-1 MEETINGS					
14:20 - 14:40	NETWORKING / 1-1 MEETINGS					
14:40 - 15:10	revvity signals **OPENING KEYNOTE PRESENTATION: New Modalities in Drug Discovery: Navigating Informatics Challenges** PRESENTER: Zev Wisotsky, *Director of Drug Discovery Informatics*, Revvity Signals revvity signals					
15:10 - 16:10 PHARMA/ BIOTECH	**Gene Dependency Screens and Targeted Chemical Library of Screens for Identification of Targets Relevant to Phenotypic Assays** David Winkler, *Executive Director Biology*, IFM Therapeutics	**Advances in computational models and machine learning techniques for a more precise prediction of ADME properties and process** Bertrand Le Bourdonnec, *Chief Scientific Officer*, HDAX Therapeutics	**Evaluating engineered organ-on-chip technology and other multicellular technologies to interrogate complex pharmacology and build understanding of human translation** Hongwei Han, *Associate Director, Head of In Vivo Pharmacology*, Generate:Biomedicines	**Biophysical Methods for Visualizing Drug-Target Interactions: Solutions for membrane targets** Laura Zawadzke, *Executive Director of Chemical and Structural Biology*, LifeMine Therapeutics	**Decoding Omics Data Interpretation, Integration, and Application in Drug Discovery through the lens of In Silico Biology** Changyun Hu, *Chief Scientific Officer*, Adept Therapeutics	**Assessing Financing Models: Which Path Fits Your Organization** Deepika Sharma Das, *Director, Portfolio Strategy & Partnerships, Global Research & Early Development*, Novo Nordisk
16:10 - 16:30	AFTERNOON REFRESHMENT BREAK					
16:30 - 17:00	**PANEL DISCUSSION: Innovative Financing Models for Drug Discovery and Development** CHAIRPERSON: Bertrand Le Bourdonnec, *Chief Scientific Officer*, HDAX Therapeutics PANELIST: Huseyin Mehmet, *Executive Director, New Ventures*, University of Massachusetts Medical School PANELIST: Larry R. Brown, *Executive Vice President, Chief Scientific Officer*, Noveome Biotherapeutics, Inc. PANELIST: Kyriakos Economides, *Vice President*, Ampersand Biomedicines					
17:00 - 18:00	DRINKS & CANAPES RECEPTION					

Event Day | Keynote Presentations

A great way to open the roundtable discussions is through a timely presentation from a top-tier biotech/pharmaceutical company. Listen as we hear this 30-minute exposition on this meeting's pressing topic.

08:30 - 09:00 ET **OPENING KEYNOTE PRESENTATION**

An Emerging Paradigm: Cellular Therapeutics without Cells

- **ST266: Placenta harvested amnion cell secretome**
- **Promotes cell survival: Anti-inflammatory, neuroprotective, anti-apoptotic**
- **Necrotizing Enterocolitis (NEC): Devastating orphan GI disease of premature neonates**
- **Preclinical efficacy translation to clinical trial**

Larry R. Brown
Executive Vice President, Chief Scientific Officer
Noveome Biotherapeutics, Inc.

ABOUT THE SPEAKER

Dr. Larry Brown obtained his doctorate with Professor Robert Langer at the Massachusetts Institute of Technology. His career focuses on biotechnology-based therapeutics and drug delivery systems. He played key roles for biotechnology companies such as Enzytech (now Alkermes) and Baxter Healthcare. He is a mentor to academic investigators at MIT's Deshpande Center for Innovation. He currently serves as Chief Scientific Officer and Executive Vice President at Noveome Biotherapeutics Inc., where he has led the translation of Noveome's ST266 product from the laboratory into the clinic. He is an author and inventor of over 100 publications and patents.

14:40 - 15:10 ET **AFTERNOON KEYNOTE PRESENTATION**

New Modalities in Drug Discovery: Navigating Informatics Challenges

Zev Wisotsky
Director of Drug Discovery Informatics
Revvity Signals

ABOUT THE SPEAKER

Zev Wisotsky is Director of Drug Discovery Informatics at Revvity Signals. His scientific training and research background includes neuroscience, biochemistry, molecular biology and drug discovery. He has spent more than eight years in software in go-to-market teams across industries with a heavy focus on biopharma/biotech R&D.

16:30 - 17:00 ET **PANEL DISCUSSION**

Innovative Financing Models for Drug Discovery and Development

CHAIRPERSON
Bertrand Le Bourdonnec
Chief Scientific Officer
HDAX Therapeutics

PANELIST
Huseyin Mehmet
Executive Director, New Ventures
University of Massachusetts Medical School

Larry R. Brown
Executive Vice President, Chief Scientific Officer
Noveome Biotherapeutics, Inc.

Kyriakos Economides
Vice President
Ampersand Biomedicines

ABOUT THE SPEAKER

Dr. Le Bourdonnec has over 20 years experience in the Biotech industry. He advanced, throughout his career, a number of projects from Research to Development across various disease areas including pain, GI disorders, infectious diseases, neurodegeneration, and oncology. He's currently Chief Scientific Officer at HDAX Therapeutics. Prior to HDAX, Dr. Le Bourdonnec served in various R&D leadership roles at small to mid-size Biotechs including Deciphera, Yumanity, Cubist and Adolor. He holds a Chemical Engineering degree and a PhD in Organic Chemistry from the University of Lille (France). Dr. Le Bourdonnec is an inventor on over 90 patents and has published over 30 scientific articles.

Event Day

TRACK 1

Target Identification & Hit Validation

Improving efficiency in finding novel therapeutic targets continues to be an immediate priority and hurdle in the pharma and biotech industry. This track aims to explore the undruggable space for utilizing AI/ML, optimizing target identification pathways and many more. How can we ensure the next druggable target frontier stays viable?

08:00 - 08:30 EST **BREAKFAST & REGISTRATION**

08:00 - 08:30 EST **OPENING KEYNOTE PRESENTATION**
See Page 6

09:00 - 10:00 EST **ROUNDTABLE 1**

Moving from target identification to novel small molecule leads: Strategies for target validation, defining a target modulation profile, and setting up a successful hit-ID campaign

Andrea Weston
Executive Director, Cellular, Genomic, and Protein Sciences
Pfizer

ABOUT THE SPEAKER
Andrea Weston is an Executive Director in Discovery Sciences at Pfizer. She leads a broad group of scientists in generation of protein reagents, cellular models, in vivo mouse models and cellular pharmacology assays. Andrea also oversees the functional genomics team focused on target identification and mechanistic studies to understand target biology and to deconvolute small molecule mechanisms of action. Prior to joining Pfizer in 2016, Andrea led research groups in lead discovery, cell biology and functional genomics at Bristol-Myers Squibb. She received her Ph.D. in Physiology from the University of Western Ontario and completed Postdoctoral studies at the Institute for Systems Biology and at Pfizer.

10:00 - 11:05 EST **REFRESHMENT BREAK & NETWORKING / 1-1 MEETINGS**

11:10 - 12:10 EST **SOLUTION FOCUS ROUNDTABLE 2**

Recent Headways into PROTACs, Molecular Glues, PPIs as Pharmacological Targets

- 5 years into PROTACs for drug discovery
- Progress in target validation in the PPI space
- Novel assays and AI interventions
- Are molecular glues the next big thing in drug discovery?

Carlos Pedraza
AVP Biology
Sai Life Sciences

ABOUT THE SPEAKER
Carlos Pedraza is an expert discovery biologist with over 15 years of experience in small molecule drug discovery in the fields of neuroscience, neurodegeneration, neuropsychiatry and neuroimmunology. He has extensive expertise in early target identification, scientific evaluation, feasibility assessment and experimental validation of novel pharmacological targets from concept to portfolio entry, IND and early clinical development.

12:15 - 13:15 EST **ROUNDTABLE 3**

Enumerating Criteria Selection Of Appropriate Modalities And Hit ID Strategies For First In Class Targets

- Consideration for the selection of the appropriate drug modality (small molecule, peptide, antibody, siRNA, ASO, etc.)
- Is an oral drug always preferable over an injectable drug?
- Hit ID strategies
  a) Potential approaches for hit ID
    I. Choice of the primary and counter-screen assays
    II. Single vs multipronged approaches
    III. Large screen vs iterations of smaller screens and desirable library sizes
  b) Hit validation

Martin Marro
Executive Director, Cell Pharmacology, Obesity & Complications
Eli Lilly and Company

ABOUT THE SPEAKER
Martin is a seasoned cell pharmacologist and drug hunter with almost 20 years of expertise in drug discovery. He has led multiple projects in either big pharma or biotech companies and has a track record of applying breakthrough science to the discovery of novel drugs targeting multiple target classes. Martin has a strong expertise in early drug discovery (target ID and validation, hit ID, hit-to-lead, lead optimization) involving different modalities (small molecule, peptides, protein/antibodies) across various diseases (metabolic, cardiovascular, gastrointestinal). Martin's efforts have contributed to the discovery of multiple development candidates, some of which reached clinical trials.

13:15 - 14:40 EST **REFRESHMENT BREAK & NETWORKING / 1-1 MEETINGS**

14:40 - 15:10 EST **AFTERNOON KEYNOTE PRESENTATION**
See Page 6

15:10 - 16:10 EST **ROUNDTABLE 4**

Gene Dependency Screens and Targeted Chemical Library of Screens for Identification of Targets Relevant to Phenotypic Assays

- HTS hits coming from phenotypic screens require intensive deconvolution experiments
- How gene dependency and targeted chemical library screening is aiding not only target discovery, but also aiding HTS hit deconvolution efforts
- Strategies for gene dependency screens (bulk CRISPR library screening) in phenotypic assays without a live/dead type of readout
- Integration of machine learning/AI into the target discovery and hit deconvolution process

David Winkler
Executive Director Biology
IFM Therapeutics

ABOUT THE SPEAKER
David Winkler has small molecule and antibody therapeutic drug discovery experience from project inception through to early development, with significant contributions to projects in bone, inflammation, immunology, oncology, immuno-oncology, and neuro-degradation/ neuro-inflammation therapeutic areas. Focuses include project biology through DC selection, translational biology, pre-clinical pharmacology, disease and target engagement biomarkers, and regulatory submissions. David's success has been documented as an author on impactful papers, patents, invited presentations, and importantly drug discovery programs that have progressed into and through development. These include contributions to 7 programs that progressed into clinical development, two of which have become approved drugs. David currently is consulting for IFM Therapeutics and other large and small companies, with a strong interest in developing start-ups. Previously David was Executive Director of Biology and Translational at IFM, Director of Pharmacology (oncology, inflammation, immune-oncology) at Infinity Pharmaceuticals, Principal Scientist (Inflammation)at Wyeth/Pfizer, and a Scientist at Celltech (bone biology). David holds a BS in Biology from Reed College and a PhD in Biochemistry from Harvard University.

16:10 - 16:30 EST **AFTERNOON REFRESHMENT BREAK**

16:30 - 17:00 EST **PANEL DISCUSSION**
See Page 6

17:00 - 18:00 EST **DRINKS & CANAPES RECEPTION**

Event Day

TRACK 2

DMPK / ADME & Toxicology

A key idea in biology is that structure, to a large extent, dictates function. The rapid development of sensitive biophysical methods and emerging technologies that interrogate compound properties and mechanisms of action is transforming drug discovery.

08:00 - 08:30 EST **BREAKFAST & REGISTRATION**

08:00 - 08:30 EST **OPENING KEYNOTE PRESENTATION**
See Page 6

09:00 - 10:00 EST **ROUNDTABLE 1**

Assessing current advancements in PBPK absorption modeling and its challenges

- Integration of PBPK modeling with drug discovery and development through Model Informed Drug Development - Pros and Cons
- Application and challenges of PBPK modeling to new modalities such as Antibody-Drug-Conjugates (ADCs), Protein degraders and Peptides
- PBPK modeling and DDI predictions - Gaps and Challenges
- Future Directions

Prasoon Chaturvedi
Vice President, Head of DMPK
C4 Therapeutics

ABOUT THE SPEAKER
Prasoon Chaturvedi, Ph.D., currently leads the DMPK efforts in the protein degrader space as Vice President, DMPK, at C4 Therapeutics in Watertown, MA. Over the last two decades, Prasoon has worked with numerous cutting-edge technologies to drive drug development endeavors in multiple therapeutic areas including infectious disease, oncology, hematology, cardiovascular, inflammation and rare diseases leading to multiple successful IND, CTA, and NDA filings and has made key DMPK contributions for several marketed drugs including NUZYRA® and ONPATTRO®. Prasoon holds a Ph.D. from IIT, Roorkee (India), and did his post-doctoral training at E.K. Shriver Center of Harvard Medical School, MA.

10:00 - 11:05 EST **REFRESHMENT BREAK & NETWORKING / 1-1 MEETINGS**

12:15 - 13:15 EST **ROUNDTABLE 3**

Utility of Microphysiological Systems in the Drug Development of Oligonucleotide Therapeutics

- Discuss the use of microphysiological systems (MPS) for high-throughput toxicity screening, ADME (Absorption, Distribution, Metabolism, and Excretion) studies, and prediction of drug safety profiles
- Highlight the potential of MPS to reduce animal use and improve the translation of in vitro findings to in vivo outcomes from regulatory perspective
- Reflect on MPS ability to provide mechanistic insights into drug behavior, optimize delivery systems, and characterize pharmacokinetics, pharmacodynamics, and safety of oligonucleotide therapeutics
- Understand the capabilities and limitations for MPS systems

Mohammad Shadid
Vice President, Preclinical Development
Korro Bio

ABOUT THE SPEAKER
Mohammad Shadid is a distinguished professional who has successfully transitioned drug assets from early research to multiple phase 1 clinical trials. He has co authored IND filings, IBs, and clinical protocols, ensuring regulatory compliance and achieving key milestones. He led teams to support IND filings. He managed multiple CROs for ADME, pharmacology, PK/PD, GLP toxicology, biomarkers, and IND-enabling studies. Shadid has generated impactful IR data for press releases, fundraising, and investor meetings. As a cultural champion, he led diversity, inclusion, and equity initiatives, managed teams, established R&D governance, and supported organizational growth.

13:15 - 14:40 EST **REFRESHMENT BREAK & NETWORKING / 1-1 MEETINGS**

14:40 - 15:10 EST **AFTERNOON KEYNOTE PRESENTATION**
See Page 6

15:10 - 16:10 EST **ROUNDTABLE 4**

Advances in computational models and machine learning techniques for a more precise prediction of ADME properties and process

- How to best integrate and harmonize the growing amount of ADME-Tox data sets to guide drug discovery effort?
- Review of open source ADME-Tox data platforms: users' experience
- Leveraging AI and machine-learning techniques to select the most promising leads and streamline the ADME-Tox lead optimization process: practical examples/ case studies

Bertrand Le Bourdonnec
Chief Scientific Officer
HDAX Therapeutics

ABOUT THE SPEAKER
Dr. Le Bourdonnec has over 20 years experience in the Biotech industry. He advanced, throughout his career, a number of projects from Research to Development across various disease areas including pain, GI disorders, infectious diseases, neurodegeneration, and oncology. He's currently Chief Scientific Officer at HDAX Therapeutics. Prior to HDAX, Dr. Le Bourdonnec served in various R&D leadership roles at small to mid-size Biotechs including Deciphera, Yumanity, Cubist and Adolor. He holds a Chemical Engineering degree and a PhD in Organic Chemistry from the University of Lille (France). Dr. Le Bourdonnec is an inventor on over 90 patents and has published over 30 scientific articles.

16:10 - 16:30 EST **AFTERNOON REFRESHMENT BREAK**

16:30 - 17:00 EST **PANEL DISCUSSION**
See Page 6

17:00 - 18:00 EST **DRINKS & CANAPES RECEPTION**

Event Day

TRACK 3

In Vivo and In Vitro Pharmacology

A primary source of drug candidate trial failure is attributed to inadequate efficacy and safety profiles. This track serves to highlight key topics and pressing challenges within the areas of drug metabolism, biotransformation and drug toxicity.

08:00 - 08:30 EST BREAKFAST & REGISTRATION

08:30 - 09:00 EST OPENING KEYNOTE PRESENTATION
See Page 6

09:00 - 10:00 EST ROUNDTABLE 1

Enhancing preclinical dose projection with appropriate biomarkers to facilitate clinical development

- In Vitro to In Vivo correlations
- In Vitro reductionist approaches vs complex organoids/tissues – what works best when/where/why
- In Vivo PK/PD models and Efficacy models for dose projection
- Biomarker selection to enable target coverage and human translation

Cara Williams
Vice President Head of Preclinical Biology, Inflammation & Immunology Research Unit
Pfizer

ABOUT THE SPEAKER

Cara Williams earned her PhD (Immunopharmacology), from Liverpool University, England UK. During her PhD studies she completed an internship at Boots/BASF/Knoll laboratories in Nottingham England where she found her passion for drug discovery and drug development. Following her PhD she completed a short postdoc at Liverpool University in the Department of Bioengineering before moving to the USA to embrace her love of mast cells; that annoying culprit involved in such things as anaphylaxis, allergy, asthma, worm and tick expulsion, itch, and the list continues to grow! She completed her postdoctoral studies on mast cell biology at Harvard University- Beth Israel Deaconess Medical Center. She then moved to Stanford University, Palo Alto CA to continue her research into mast cell function in health and disease. Nevertheless, as a devoted drug discovery pharmacologist with an interest in turning basic research into new therapeutic breakthroughs for patients, Cara moved into the preclinical drug discovery world of biotech/pharma joining Genetics Institute/AHP, Wyeth, Pfizer and later to Boehringer Ingelheim in Germany. She returned to Pfizer USA in 2019 and now leads the Preclinical Biology research line within the Inflammation & Immunology Research Unit at the Cambridge MA site within Pfizer PRDM.

10:00 - 11:25 EST REFRESHMENT BREAK & NETWORKING / 1-1 MEETINGS

11:10 - 12:10 EST ROUNDTABLE 2

Opportunities and risks in the preclinical development of molecules that do not cross react with rodents

- Lack of mouse models - Cross reactivity with rodents makes it harder for efficacy testing
- Regulatory hurdles – Requirement of data animal models to support clinical studies.
- Humanized models - development of KI/KO mice to help understand preclinical efficacy

Anitha Krishnan
Executive Director, Research
Aviceda Therapeutics

ABOUT THE SPEAKER

With a robust background in neuro-ocular immunology and a hands-on approach to disease models for CNS and ocular diseases, Anitha's journey from the bench to leading a drug development team showcases a deep understanding of the biological and analytical challenges within the biopharma industry. Her experience has not only been pivotal in navigating the complexities of drug development but also in mastering the essential experiments that drive progress in this field. The knowledge acquired over the past five years at Aviceda, especially the ability to bridge CMC with biological efficacy, stands as a testament to success. Leveraging her experience from Harvard, and effectively addressing critical development aspects paving the way towards successful clinical trials, underscoring her role as a key contributor to the biopharma sector. Her expertise is ever-evolving in this landscape of biotechnology, where understanding the multifaceted nature of drug development is crucial for innovation and advancement.

13:15 - 14:40 EST REFRESHMENT BREAK & NETWORKING / 1-1 MEETINGS

14:40 - 15:10 EST AFTERNOON KEYNOTE PRESENTATION
See Page 6

15:10 - 16:10 EST ROUNDTABLE 4

Evaluating engineered organ-on-chip technology and other multicellular technologies to interrogate complex pharmacology and build understanding of human translation

- Importance of in vivo testing for regulatory filings
- Challenges and opportunities in in vivo testing
- Emerging technologies, such as 3D organoids, creating new possibilities

Hongwei Han
Associate Director, Head of In Vivo Pharmacology
Generate:Biomedicines

ABOUT THE SPEAKER

Hongwei Han has been serving as the Associate Director, Head of In Vivo Pharmacology at Generate Biomedicines since December 2022. Before joining Generate, Hongwei held the position of Principal Scientist in the Immunology & Inflammation Therapeutic Area at Sanofi. In this role, he spearheaded the preclinical research team on pivotal projects, including Dupixent, Lunsekimig, Itepekimab, Rilzabrutinib, and Tolebrutinib. Dr. Han earned his Ph.D. in Immunology from the University of Tokushima, Japan, in 2007. He subsequently undertook postdoctoral training at the Benaroya Research Institute in Seattle. There, he made significant discoveries regarding the roles of TSLP and IL-33 in the atopic march, elucidating the progression from atopic dermatitis to asthma and food allergies. Over the course of his career, he has contributed to over 20 publications in the fields of immunology and preclinical drug discovery.

16:10 - 16:30 EST AFTERNOON REFRESHMENT BREAK

16:30 - 17:00 EST PANEL DISCUSSION

17:00 - 18:00 EST DRINKS & CANAPES RECEPTION

Event Day

TRACK 4

Structural Biology and Biophysics

A key idea in biology is that structure, to a large extent, dictates function. The rapid development of sensitive biophysical methods and emerging technologies that interrogate compound properties and mechanisms of action is transforming drug discovery.

08:00 - 08:30 EST BREAKFAST & REGISTRATION

08:30 - 09:00 EST OPENING KEYNOTE PRESENTATION
See Page 6

09:00 - 10:00 EST ROUNDTABLE 1

Unveiling Drug Targets: The Crucial Role of Structural Biology and Biophysics in Modern Drug Discovery

- When is the correct time (stage gate) to deploy structural biology and biophysics resources on a program?
- What is the right mix of internal vs. outsourced support for structure and biophysics?
- How to deploy ML/AI for structural biology or lead discovery efforts?
- When and why to invest in a cryo-EM vs. X-ray-based structure platform?
- What are the new, disruptive technologies in biophysics?

Kevin Knockenhauer
Associate Director
Accent Therapeutics

ABOUT THE SPEAKER
Kevin is the Head of Biophysics at Accent Therapeutics, where he leads a team focused on targeting RNA-modifying enzymes with small molecule inhibitors. Prior to Accent, he led and supported programs in both biologics and small molecule drug discovery at Sanofi, Bioverativ, and Civetta Therapeutics. Kevin started his decade in industry as a Novartis postdoc, tackling biophysics of integral membrane proteins. He received his PhD in structural biology from the MIT Department of Biology. Kevin's main scientific focus is the application of biophysical techniques to early-stage drug discovery.

10:00 - 11:05 EST REFRESHMENT BREAK & NETWORKING / 1-1 MEETINGS

11:10 - 12:10 EST SOLUTION FOCUS ROUNDTABLE 2

Conceptualizing Drug-Target Interactions at the Next Level: Targeted Protein Degraders

- Overview of biophysical methods: Advances and limitations
- Fragment-based drug design, high-throughput screening, and other biophysical approaches to enhance drug-target visualization
- Challenges to modeling and confirming ternary complex formation and dynamics
- Multimodal approaches and technological advancements
- Future directions

Jonathan Castillo
Associate Director Biology & Biophysics
Sai Life Sciences

ABOUT THE SPEAKER
Research scientist with over 12 years of experience in small molecule drug discovery and biologics development in the fields of infectious disease, oncology, and tumor immunology. Extensive expertise in assay development, target identification, and hit validation.

12:15 - 13:15 EST ROUNDTABLE 3

Applications of Structural Biology and Biophysics in Cell and Gene Therapies

Dhruv Sethi
Senior Director, Discovery
Obsidian Therapeutics

ABOUT THE SPEAKER
Speaker TBC

13:15 - 14:40 EST REFRESHMENT BREAK & NETWORKING / 1-1 MEETINGS

14:40 - 15:10 EST AFTERNOON KEYNOTE PRESENTATION
See Page 6

15:10 - 16:10 EST ROUNDTABLE 4

Biophysical Methods for Visualizing Drug-Target Interactions: Solutions for membrane targets

Laura Zawadzke
Executive Director of Chemical and Structural Biology
LifeMine Therapeutics

ABOUT THE SPEAKER
Expert Enzymologist and In Vitro Pharmacologist with in depth HTS experience:

• Industry experience acquired in two different pharmaceutical company settings (BMS and Pfizer) and several Biotechnology settings.
• Core competencies include: target evaluation, development and use of assays in both HTS and SAR efforts for enzymes, membrane receptors, and ion channels, mechanistic studies and biological evaluation of enzyme inhibitors and receptor agonists/antagonists as applied to drug discovery.
• Extensive "hands-on" knowledge of biochemical and cellular in vitro pharmacological and chemical concepts and methods.
• Demonstrated success in cross departmental team efforts to develop data analysis software and HTS data assessment methods
• Experienced in leading teams, managing projects, and developing personnel.

16:10 - 16:30 EST AFTERNOON REFRESHMENT BREAK

16:30 - 17:00 EST PANEL DISCUSSION
See Page 6

17:00 - 18:00 EST DRINKS & CANAPES RECEPTION

Event Day

TRACK 5

In Silico Biology

The utility of computational methods is widely used in various stages of drug discovery and development. From aiding target ID & validation, limiting the use of animal models in pharmacology to aiding rational drug design, this track will explore novel approaches and application of in silico techniques to maximize productivity towards clinical success.

08:00 - 08:30 EST BREAKFAST & REGISTRATION

08:30 - 09:00 EST OPENING KEYNOTE PRESENTATION
See Page 6

09:00 - 10:00 EST ROUNDTABLE 1

Evaluating practical uses of latest AI/ML tools to expedite and increase efficiency in drug discovery process

- Where do AI/ML tools currently have the greatest impact in the drug discovery process
- What are the gaps in drug discovery were AI/ML tools could have greater impact
- Are there barriers to uptake of newer technologies and how can they be addressed
- Can open innovation including academic/industry partnerships play a role in expanding use of the tools

Diane Joseph-McCarthy
Executive Director,
Bioengineering Technology & Entrepreneurship Center
Boston University

ABOUT THE SPEAKER

Diane Joseph-McCarthy is the Executive Director of the Bioengineering Technology & Entrepreneurship Center and Professor of the Practice in Biomedical Engineering at Boston University. Prior to that, she was a senior life science executive with over 20 years of drug discovery, development, and leadership experience. She was SVP of Discovery & Early Development at EnBiotix, a bioengineering company focused on respiratory and rare disease. She was an Associate Director at AstraZeneca, where she led a global team and task forces to transform Infection's early portfolio. At Wyeth, she held positions of increasing responsibility. Diane received her PhD from MIT and was a postdoctoral fellow at Harvard University/Harvard Medical School.

10:00 - 11:05 EST REFRESHMENT BREAK & NETWORKING / 1-1 MEETINGS

12:15 - 13:15 EST ROUNDTABLE 3

Harnessing the promise of generative AI to transform drug discovery hence forward

- Accurate benchmarks to compare different generative methods
- Limited or low-quality biological training data.
- Regulatory guardrails for generation of biological constructs
- Usage of generative AI to both determine what decisions to take and for drafting scientific papers
- Improvements on basic machine learning concepts tailored towards biology

Jason Wu
Machine Learning Scientist II
Sanofi

ABOUT THE SPEAKER

Jason Wu is a Machine Learning Scientist in the Genomic Medicine Unit at Sanofi, based in Waltham, MA. He joined Sanofi in 2022 as a member of the AAV Technologies Laboratory, a platform group focused on AAV capsid engineering and AAV immunology. Jason obtained his B.S. and M.S.E. in Chemical and Biomolecular Engineering from Johns Hopkins University. Prior to joining the GMU, he worked on a variety of machine learning related topics including defect detection for spice packaging at McCormick and automatic segmentation of cat brain MRIs at the Center for Imaging Science at Johns Hopkins University.

13:15 - 14:40 EST REFRESHMENT BREAK & NETWORKING / 1-1 MEETINGS

14:40 - 15:10 EST AFTERNOON KEYNOTE PRESENTATION
See Page 6

15:10 - 16:10 EST ROUNDTABLE 4

Decoding Omics Data Interpretation, Integration, and Application in Drug Discovery through the lens of In Silico Biology

- Computational genomics and proteomics: GWAS & TCGA etc omics studies and their role in drug discovery; in silico tool(s) for predicting protein function and interactions from genomic data; non-coding RNA (microRNA for physiology and medicine Nobel Prize)
- In silico drug design: Better for small molecule, less successful for large molecule; Biology understanding (particularly for GPCR) is a key to design the right molecule for right biology
- AI (this year's physics Nobel prize)/ML and in silico biology: integrating AI models to enhance in silico predictions of drug efficacy; Using deep learning algorithms for in silico prediction of protein folding and interaction networks; how to obtain relevant high quality data for AI/ML and data sharing issue

Changyun Hu
Chief Scientific Officer
Adept Therapeutics

ABOUT THE SPEAKER

Changyun Hu is the CSO of Adept Therapeutics Inc, focusing on developing antibody-mediated immunotherapies for cancer patients. Changyun's effort has contributed to several patents and multiple IND filings and is known for his expertise in antibody drug discovery against multi-transmembrane targets such as GPCRs. He was one of the first few that discovered the regulatory role of B cells in autoimmune setting. He has established a track record in the scientific community with 20+ peer-reviewed highly-cited publications. Changyun holds a PHD and is a seasoned drug hunter with extensive experience from target identification and validation, antibody discovery and optimization, to IND filing.

16:10 - 16:30 EST AFTERNOON REFRESHMENT BREAK

16:30 - 17:00 EST PANEL DISCUSSION
See Page 6

17:00 - 18:00 EST DRINKS & CANAPES RECEPTION

new for 2024

Event Day

TRACK 6

Strategic Partnerships, Investment & Collaborations

Bringing together Managing Partners & C-level executives from investment firms supporting innovation in the clinical trial process, strategies from pharma companies and corporate arms with a vested interest in driving this innovation. It comes with the purpose of identifying and collaborating with potential drug development partners whilst addressing industry challenges in this area

12:15 - 13:15 EST ROUNDTABLE 3

Leveraging on academic partnerships to further drug discovery and development operations

- How to match assets with deal types – choosing the right biopharma partner
- Developing and selling early stage discoveries
- Nuances of deal making between academic institutions and the biopharma industry

Huseyin Mehmet
Executive Director, New Ventures
University of Massachusetts Medical School

ABOUT THE SPEAKER

Huseyin Mehmet is a drug hunter and research scientist with >35 years' experience in basic and clinical academic research and in pharmaceutical / biotechnology drug discovery. He received his PhD from the Medical Research Council in the UJ and went on to work at University College London, the Imperial Cancer Research Fund (now Cancer Research UK), Cold Spring Harbor Lab, USA and then took a faculty position at Imperial College School of Medicine. There his work focused on cerebral hypoxic ischemic injury in neonates and he was part of the team that developed mild hypothermia for the treatment of birth asphyxia. In 2006 Huseyin left the UK to join Merck and Co, in the USA. He worked in biomarker discovery, target identification and several drug discovery programs up to clinical candidate selection. For the next few years, he took on roles with increasing responsibility in several biotech companies and also consulted for a number of start-up companies working with prominent VC firms (e.g. Atlas Ventures and Versant Ventures). Since 2021, Huseyin has led the New Ventures team in the BRIDGE Innovation and Business Development office at UMass Chan Medical School, where he is responsible for the scientific partnering of intellectual property arising from faculty discoveries.

15:10 - 16:10 EST ROUNDTABLE 4

Assessing Financing Models: Which Path Fits Your Organization

Deepika Sharma Das
Director, Portfolio Strategy & Partnerships, Global Research & Early Development
Novo Nordisk

ABOUT THE SPEAKER

Deepika Das holds the position of Director, Research Portfolio Strategy and Partnerships at Novo Nordisk. Deepika has a Ph.D. in cellular and molecular biology, and she conducted her Post Doctoral Fellowship at Harvard Medical School (DFCI). Her industry career started at Takeda Pharmaceuticals where she held different roles in Oncology Portfolio Strategy & Operations, Rare Disease Business Development and GI Project & Alliance Management groups. Prior to joining Novo Nordisk, she served as the Head of Portfolio Management and Operations at Sanofi and managed a diversified portfolio of therapeutics for neurodegenerative disorders and rare diseases, including metabolic, hematological, and neuro-muscular disorders.



Pharma
FEATURES

Find your new partner,
explore our digital storefronts

www.pharmafeatures.com

Contact us to discuss how we can help generate growth for your business

Dex Marco Guibelondo
Marketing Content Writer, Proventa International
Editor-in-Chief, PharmaFEATURES

dex@proventainternational.com

PROVENTA INTERNATIONAL

2025 Strategy Meeting Calendar

MAY

Boston/Cambridge MA - US East Coast

MAY 7 WED
CHEMISTRY MANUFACTURING CONTROL
CMC Strategy Meeting 2025
Le Meridien Boston Cambridge

MAY 8 THUR
MEDICINAL CHEMISTRY
Medicinal Chemistry Strategy Meeting 2025
Le Meridien Boston Cambridge

Princeton/New Jersey - US East Coast

MAY 14 WED
MEDICINAL CHEMISTRY
Medicinal Chemistry Strategy Meeting 2025
Hyatt Regency Princeton

MAY 15 THUR
CLINICALOPERATIONS & CLINICALTRIALSUPPLYCHAIN
Clinical Operations & Clinical Trial Supply Chain Strategy Meeting 2025
Hyatt Regency Princeton

NOVEMBER

San Diego - US West Coast

NOV 12 WED
MEDICINAL CHEMISTRY
Medicinal Chemistry Strategy Meeting 2025
Hard Rock Hotel San Diego

NOV 13 THUR
CLINICALOPERATIONS & CLINICALTRIALSUPPLYCHAIN
Clinical Operations & Clinical Trial Supply Chain Strategy Meeting 2025
Hard Rock Hotel San Diego

Boston/Cambridge MA - US East Coast

NOV 18 TUE
CLINICALOPERATIONS & CLINICALTRIALSUPPLYCHAIN
Clinical Operations & Clinical Trial Supply Chain Strategy Meeting 2025
Le Meridien Boston Cambridge

NOV 19 WED
BIOINFORMATICS & DRUG DISCOVERY BIOLOGY
Bioinformatics Strategy Meeting 2025
Le Meridien Boston Cambridge

DRUG DISCOVERY BIOLOGY

STRATEGY MEETING EAST COAST USA 2024

Tuesday, 12th November 2024 Le Meridien Cambridge



Hotel & Venue

Le MERIDIEN

Le Méridien Boston Cambridge

Le Méridien Cambridge-MIT's elegant guest rooms and suites offer a place of luxurious sanctuary and unmatched comfort. Explore unique programs inspired by the brand's European heritage. Born in a glamorous era of travel, Le Méridien believes everyone should explore the world in style.

Hotel Details > Map & Directions >




OUR FACE TO FACE MEETING IN OCT & NOV 2024

STRATEGY MEETING EUROPE
Crowne Plaza, London Docklands

OCT 23
MEDICINAL CHEMISTRY
STRATEGY MEETING EUROPE 2024

STRATEGY MEETING EAST COAST USA
Le Meridien Boston Cambridge

NOV 11
BIOINFORMATICS & IT
STRATEGY MEETING EAST COAST USA 2024

NOV 12
DRUG DISCOVERY BIOLOGY
STRATEGY MEETING EAST COAST USA 2024

NOV 13
MEDICINAL CHEMISTRY
STRATEGY MEETING EAST COAST USA 2024

Visit us on our website to know more about our meetings

www.proventainternational.com